Summary. Vasoactive Intestinal Polypeptide (VIP) increased the release of insulin, glucagon and somatostatin from the perfused rat pancreas. The amount of these hormones released was dependent upon the prevailing glucose concentration. VIP stimulated glucagon release in the absence of glucose, while insulin and somatostatin release were increased by VIP only in the presence of glucose concentrations of 4.4 mmol/1 and above. Glucagon secretion stimulated by arginine in the presence of 4.4 mmol/1 glucose was potentiated by VIP. In contrast, VIP did not induce any further increase in the secretion of insulin and somatostatin over that stimulated by arginine. At higher concentrations of glucose (6.7, 16.7, and 33.3 mmol/1) VIP continued to stimulate insulin and somatostatin release, this effect being synergistic on early-phase insulin release. The effects of VIP on islet cells thus depend on the levels of modulating nutrients.
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Vasoactive Intestinal Polypeptide (VIP) was first isolated from porcine duodenum [22] . Using antibodies against pure porcine VIP in immunoperoxidase and immunofluorescence tests, VIP-immunoreactive cells have been detected in the islets in dog, guinea-pig, and man, but not in rats ( [2] ; Schultzberg and H6k-felt, personal communication). VIP has also been found in the central nervous system [13, 14] and in peripheral nerves [15, 19, 27, 28] . In the pancreas, VIP containing nerves have been seen in connective tissues within the exocrine pancreatic parenchyma, and also in association with islets [27] .
VIP stimulates insulin and glucagon release from isolated perfused porcine pancreas [16] as well as from dog pancreas perfused in situ [12] which, together with the occurrence of VIP in islets, suggests that the peptide may be of importance for the regulation of the secretion of islet hormones.
The present study was designed to characterize the effects of VIP on the release of insulin, glucagon, and somatostatin from the isolated perfused rat pancreas. The study was further extended to investigate the interaction of VIP, glucose, and arginine on pancreatic hormone release.
Material and Methods
Sprague-Dawley rats (Anticimex, Stockholm), weighing 200-250 g, and fed ad libitum, were anaesthetized by IP injection of 50 mg/kg of pentobarbitone and the pancreas isolated [17] . The perfusing medium, a red-cell free Krebs-Ringer bicarbonate solution containing 2g/100ml bovine serum albumin, was infused into the coeliac artery, and run into the prepared pancreas by an open circuit, a "non-recycling perfusion system" [17] . The rate of perfusion was approximately 3.0 ml/min. The pancreas was equilibrated by perfusion for 20 min before the start of the experiments.
Insulin was measured by radioimmunoassay using a rat insulin standard [10] . The sensitivity of the assay was about 300 ng/1 and the coefficient of variation + 10%. Glucagon was assayed by the charcoal separation technique with an antibody specific for pancreatic glucagon "30 K" [8] . The sensitivity of this assay was about 50 ng/1 and the coefficient of variation _+ 7%. Somatostatin was measured by a radioimmunoassay using locally produced antibodies [4] . Cross-reactivity of this antibody was less than 0.01% with insulin, glucagon, VIP, substance P, LH-RH, vasopressin, and oxitocin. The sensitivity of the somatostatin assay was about 5 ng/1 and coefficient of variation + 15%.
Pure, natural, porcine VIP was kindly provided by Professor V. Mutt, Karolinska Institute, Stockholm.
The amounts of insulin and somatostatin released were determined by integrating the areas under the respective curves. In the absence of glucose in the perfusing medium, The effect was most pronounced during the first five minutes of VIP administration. The peptide alone had no effect on insulin and somatostatin secretion. In contrast, in the presence of 4.4 mmol/1 glucose in the perfusing medium, VIP stimulated the release of insulin and somatostatin but not of glucagon ( Fig. 1 ).
Dose Dependence of the Insulin and Somatostatin Response to VIP (Fig. 2)
In these experiments, the pancreas was peffused with a medium containing 4.4 mmol/1 glucose. The lowest dose of VIP used (0.1 nmol/1) significantly enhanced insulin as well as somatostatin release. The release of these hormones was maximally stimulated by the presence of 1 nmol/1 VIP. Irrespective of the dose of VIP, insulin response was stimulated most during the first five minutes of the administration of the peptide, while somatostatin response to VIP persisted at the same level during the entire experiment (Fig. 2) . 
Interaction of Glucose and VIP on the Release of Insulin and Somatostatin (Figs. 3 and 4)
In these experiments, the pancreas was first equilibrated for 20 rain with a perfusion medium containing 3.3 mmol/1 glucose. In the control experiments, the pancreas was then stimulated by increasing glucose concentrations (6.7, 16.7, and 33.3 mmol/1). In the experiments with VIP, glucose and 1 nmol/1 of VIP were perfused simultaneously. As expected, administration of glucose induced a biphasic insulin response. Significant stimulation of insulin release was seen when the glucose concentration was increased from 3.3 mmol/l to 6.7 mmol/1. Analysis of the two series of results (Fig. 3, Table  1 ) shows that at all glucose concentrations used, VIP and glucose exerted synergistic effects on the early phase of insulin release. Late insulin release was significantly enhanced by VIP only in the presence of 6.7 mmol/] glucose. VIP significantly enhanced both the early and the late phase of somatostatin release in the presence of 6.7 mmol/1 glucose (P < 0.01) and the early phase with 16.7 mmol/1 of the hexose (Fig. 4 , Table 2 ). (Fig. 5) Arginine (20mmol/1) significantly stimulated the release of insulin, glucagon, and somatostatin from pancreas perfused with a medium containing 4.4 mmol/1 glucose. The effect was most pronounced during the first 5 min. VIP significantly enhanced arginine induced glucagon release, whereas there was no such effect on insulin and somatostatin secretion (Fig. 5) .
Effect of VIP on Arginine Induced Release of Insulin, Glucagon and Somatostatin

Discussion
VIP containing nerves occur in rat islets ( [27] ; Schultzberg and H6kfelt, personal communication). The present study demonstrates that in rat VIP stimulates the release of insulin, glucagon and somatostatin from the isolated perfused pancreas, depending on glucose concentration. VIP had a similar effect in the perfused pancreas of other species, in that it stimulated insulin and glucagon release from the porcine pancreas, and insulin and somatostatin from the canine pancreas [12, 16] . In our experimental system VIP stimulated glucagon release in the absence of glucose. In contrast, at 4.4mmol/1 glucose level, the peptide significantly enhanced the secretion of insulin and somatostatin but not of glucagon. Dependence of the effect of VIP on glucose concentration in the perfusing medium also occurs in the isolated porcine pancreas [16] . However, in the porcine pancreas, VIP stimulated glucagon release even in the presence of 5.0 mmol/1 glucose, and it was only when the glucose concentration was increased to a hyperglycaemic level (7.5mmol/1) that VIP enhanced insulin release. Furthermore, under normoglycaemic conditions in the in situ perfused cat pancreas VIP was more An important finding is that during normoglycaemia, VIP also stimulates somatostatin release. The interaction between glucose and substances releasing somatostatin is almost unknown. We have also demonstrated that, in contrast to VIP, a sulphonylurea drug (glibenclamide) markedly stimulates somatostatin release from the perfused rat pancreas in the presence of low glucose concentrations (3.3 mmol/1 or less) whereas the effect was less pronounced at 4.4 mmol/1 glucose [7] .
The significance of glucose for the effects of VIP in the pancreas is further emphasized by studies of its effects on insulin and somatostatin release induced by increasing glucose concentrations. VIP was clearly synergistic with glucose over a broad range of concentrations of this hexose (6.7 to 33.3 mmol/1). A remarkable finding was that the peptide exerted a more prominent effect on early than on late insulin and somatostatin release. This would imply that VIP sensitizes both B and D cells for the action of glucose. On the other hand, VIP seems to sensitize A but not B cells when arginine is used as stimulator.
These marked effects of VIP on the release of islet hormones are in contrast to in vivo studies. In rats, a dose as large as 2 gg/kg of VIP induced only a slight increase in serum insulin [29] . When VIP was given as a continuous IV infusion in rats at a dose of 40 ng/kg/min, there was no effect on basal or glucose or arginine induced, insulin or glucagon release (unpublished observations). The comparison between in vitro and in vivo effects of VIP suggests that, in rats, VIP plays a role in the regulation of the function of A, B, and D cells provided that the peptide released from VIP containing islet nerve terminals exerts a direct local action.
Since in the present experiments we used porcine VIP some caution is warrented when extending our results to a possible physiological significance of VIP in rat islets. Rat VIP is not available at present.
